IgAÉö²¡ÊÇÈ«ÇòÁìÓòÄÚ×î³£¼ûµÄÔ·¢ÐÔÉöÓ×Çò¼²²¡Ö®Ò»£¬£¬£¬£¬£¬£¬£¬£¬ÔÚÎÒ¹ú¼°¶«Ñǹú¶ÈÓÈΪ³£¼û¡£¡£¡£¡£¡£´óÎÞÊý»¼Õß²û·¢ÎªÉöÔಡ»ºÂý½øÕ¹£¬£¬£¬£¬£¬£¬£¬£¬Êǵ¼ÖÂÇàÄêÈËÖÕδÆÚÉö²¡µÄ×î³£¼û²¡Òò£¬£¬£¬£¬£¬£¬£¬£¬¸ø¼ÒÍ¥ºÍÉç»á´øÀ´Á˳Á³ÁµÄ¼²²¡Ö°ÊØ¡¾1¡¿¡£¡£¡£¡£¡£ÔÚIgAÉö²¡µÄÒ½Öιý³ÌÖУ¬£¬£¬£¬£¬£¬£¬£¬»¼Õß½ÌÓýÊdzÁÒª»·½Ú£¬£¬£¬£¬£¬£¬£¬£¬¶øÄ¿Ç°IgAÉö²¡»¼Õߵļ²²¡ÈÏÖª¡¢×ÔÎÒÖÎÀíÄÜÁ¦ÈÔÓнϴóÌáÉý¿Õ¼äºÍδÂú×ãÐèÒª¡£¡£¡£¡£¡£
ΪÁËÔ®ÊÖ¸ü¶àIgAÉö²¡»¼Õß»ñÈ¡ÕïÁÆÖªÊ¶¡¢Ìá¸ß¼²²¡ÖÎÀíÄÜÁ¦£¬£¬£¬£¬£¬£¬£¬£¬¡°±£ÎÀÉöÖ°ÄÜ¡ªIgAÉöÓѰٳǹ«ÒæÐÓ×±ÏîÄ¿³¤É³Õ¾»î¶¯ÔÚ918²«ÌìÌôóÒ©·¿Îåһ·µê½øÐУ¬£¬£¬£¬£¬£¬£¬£¬Í¨¹ýÏßÉÏÏßÏÂÏà½áºÏµÄÉöÓѽÌÓý»î¶¯¡¢Ò½»¼»¥¶¯¼°¿ÆÆÕ´«²¼£¬£¬£¬£¬£¬£¬£¬£¬Íƶ¯»¼ÕßÔçÕïÔçÖΣ¬£¬£¬£¬£¬£¬£¬£¬´Ó¶øÑÓ»º¼²²¡½øÕ¹£¬£¬£¬£¬£¬£¬£¬£¬Ìá¸ßÉúÑÄÖÊÁ¿¡£¡£¡£¡£¡£
³¤É³ÊÐÉö´È¹«Òæ·þÎñÖÐÉúÀíʳ¤ºî¼ÑÏÖ³¡Ö´ǣ¬£¬£¬£¬£¬£¬£¬£¬·ÖÏí¹«ÒæÁ¦Á¿ÔÚÉö²¡Ôçɸ¡¢»¼Õß½ÌÓý¼°ÉúÀíÖ§³ÖµÈ·½ÃæµÄʵ¼Ê¾Ñé¡£¡£¡£¡£¡£
±¾´Î»î¶¯Ô¼ÇëÁËÖÐÄÏ´óÑ§ÏæÑÅÈýÒ½ÔºÉöÄÚ¿ÆÁõ¼Íʵ½ÌÊÚ´øÀ´Ö÷Ìâ½²×ù£¬£¬£¬£¬£¬£¬£¬£¬ÒÔÕæÊµ°¸Àý½â˵IgAÉö²¡µÄ·¢²¡²û·¢¡¢ÉúÑÄÒûʳ׼Ôò¡¢IgAÉö²¡Ò©ÎïÕïÁƹ滮µÈ֪ʶ£¬£¬£¬£¬£¬£¬£¬£¬¼¤Àø¸÷ÈËÕýÈ·Òâʶ¼²²¡£¡£¡£¡£¡£¬£¬£¬£¬£¬£¬£¬£¬×öµ½ÔçÕï¡¢ÔçÖΡ¢Ôç°²ÐÄ¡£¡£¡£¡£¡£
ÔÚÏÖ³¡´ðÒÉ»·½Ú£¬£¬£¬£¬£¬£¬£¬£¬Áõ¼Íʵ½ÌÊÚÕë¶Ô»¼Õß¹ØÇеÄÎÊÌâÖðÒ»½â´ð¡£¡£¡£¡£¡£¹ØÓںöàÉöÓѹØÇеIJ¼µØÄ峦ÈܽºÄÒµÄÎÊÌ⣬£¬£¬£¬£¬£¬£¬£¬Áõ½ÌÊÚ½â´ð£º²¼µØÄ峦ÈܽºÄÒ£¨Ä͸³¿µ?NEFECON?£©ÊÇÈ«ÇòÊ׸ö°ÐÏòIgAÉö²¡Ô´Í·–³¦Â·ð¤Ä¤ÃâÒߵĶÔÒòÒ½ÖÎÐÂÒ©£¬£¬£¬£¬£¬£¬£¬£¬ÊÇÊ׸öͬʱ±»ÃÀ¹úFDA¡¢Å·ÖÞEMA¡¢ÖйúNMPAÈý´óȨÍþÒ©¼à»ú¹¹ºË×¼ÓÃÓÚÒ½ÖÎIgAÉö²¡µÄ´´ÐÂÒ©Î2-7¡¿£¬£¬£¬£¬£¬£¬£¬£¬ÓµÓгÁ´óÁÙ´²Òâ˼¡£¡£¡£¡£¡£ËüºÏÓÃÓÚÓµÓнøÕ¹·çÏÕµÄÔ·¢ÐÔIgAÉö²¡³ÉÄ껼Õߣ¬£¬£¬£¬£¬£¬£¬£¬Äܹ»Ï÷¼õÉöÖ°ÄÜʧÂ䣬£¬£¬£¬£¬£¬£¬£¬Í¬Ê±½µµÍµ°°×Äò¡¢¸ÄÉÆÑªÄò¡£¡£¡£¡£¡£
²¼µØÄ峦ÈܽºÄÒ£¨Ä͸³¿µ?NEFECON?£©ÔÚ918²«ÌìÌôóÒ©·¿ÓÐÊÛ£¬£¬£¬£¬£¬£¬£¬£¬ÎÒÃÇ»ý¼«¹²Í¬ÁÙ´²ÐèÒª£¬£¬£¬£¬£¬£¬£¬£¬ÊµÊ±ÎÈÍ׵ؽ«Ò©Æ·ÅäË͵½»¼Õß±ØÒªµÄ´¦Ëù¡£¡£¡£¡£¡£
918²«ÌìÌò¿ÃÅDTPÒ©·¿ÐÅÏ¢Ò»ÀÀ£º
²Î¿¼Îļþ£º
1.ÐÂÒ©ÀûÓúÍÒ½ÖÎÕ½Êõת±äÓÐÍû¸ÄÉÆIgAÉö²¡»¼ÕßµÄÔ¤ºó[J]. ÖлªÒ½Ñ§ÐÅÏ¢µ¼±¨,2024,39(16):11. DOI:10.3760/cma.j.issn.1000-8039.2024.16.118.
2.https://www.nmpa.gov.cn/zwfw/sdxx/sdxxyp/yppjfb/20231124144653113.html.
3.FDA approves first drug to decrease urine protein in IgA nephropathy, a rare kidney disease
4.https://news.cision.com/calliditas-therapeutics/r/european-commission-approves-kinpeygo--for-adults-with-primary-iga-nephropathy,c3600434.
5.https://www.calliditas.se/en/calliditas-therapeutics-announces-full-fda-approval-of-tarpeyo-the-only-fda-approved-treatment-for-iga-nephropathy-to-significantly-reduce-the-loss-of-kidney-function/
6.https://www.everestmedicines.com/zhhans/news/yundingxinyaohezuohuobancalliditasxuanbunaifukanghuodemeiguofdawanquanpizhunyongyuzhiliaoyoujinzhanfengxiandeigashenbinghuanzhe-wulunqijixiandanbainiaoshuiping/936f18ac-566a-4b3d-8cd0-036f720b62e6/
7.https://news.cision.com/calliditas-therapeutics/r/european-commission-approves-kinpeygo--for-adults-with-primary-iga-nephropathy,c3600434.